Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 and Lenvatinib in Advanced Solid Tumors
NCT05740215Phase 2Unknown
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rulonilimab in solid tumor, endometrial cancer (EC), Cervical Cancer (CC), sponsored by Shandong New Time Pharmaceutical. Status: unknown.
02
Drugs
rulonilimab
03
Conditions
solid tumorendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05740215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740215.